4-(1H-pyrrol-3-yl)-piperidine | 881019-45-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(1H-pyrrol-3-yl)-piperidine
• 英文别名: 4-(1H-pyrrol-3-yl)piperidine
• CAS: 881019-45-0
• 化学式: C₉H₁₄N₂
• 分子量: 150.224
• InChiKey: AVGJJXQNFZILJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  4-(1H-pyrrol-3-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid benzyl ester 在 20% Pd(OH)2 on carbon 氢气 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以94%的产率得到4-(1H-pyrrol-3-yl)-piperidine
  参考文献：
  名称：

  Substituted dipiperidine CCR2 antagonists

  摘要：

  Formula (I)的替代二哌啶化合物或其盐、异构体、前药、代谢物或多型体，其为CCR2拮抗剂，可用于预防、治疗或改善需要的主体中的CCR2介导的炎症综合症、紊乱或疾病。

  公开号：

  US20060069123A1

文献信息

• [EN] SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS<br/>[FR] ANTAGONISTES ANTI-CCR2 A BASE DE DIPIPERIDINE SUBSTITUEE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2006036527A1

  公开（公告）日：2006-04-06

  Substituted dipiperidine compounds of Formula (I) or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  公式（I）的替代二哌啶化合物或其盐、异构体、前药、代谢物或多晶形式，是CCR2拮抗剂，并且在预防、治疗或改善需要此类CCR2介导的炎症综合征、疾病或疾病的受试者中有用。
• SUBSTITUTED DIPIPERDINE CCR2 ANTAGONISTS
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1802602A1

  公开（公告）日：2007-07-04
• [EN] COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES<br/>[FR] COMPOSES, DERIVES, COMPOSITIONS, LEUR PREPARATION ET LEURS UTILISATIONS
  申请人：——

  公开号：WO2003014121A9

  公开（公告）日：2004-03-25

  [EN] This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.
  [FR] L'invention concerne des composés, des compositions pharmaceutiques, et des méthodes d'utilisation desdites composés pour inhiber la PARP.
• [EN] 3 - IMIDAZOLYL- INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES<br/>[FR] 3-IMIDAZOLYL-INDOLES POUR TRAITER LES MALADIES PROLIFÉRATIVES
  申请人：NOVARTIS AG

  公开号：WO2012176123A1

  公开（公告）日：2012-12-27

  The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I), in which: R1, R2, R3 and R4 are as defined in the Summary of the Invention. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.
• Substituted dipiperidine CCR2 antagonists
  申请人：Xia Mingde

  公开号：US20060069123A1

  公开（公告）日：2006-03-30

  Substituted dipiperidine compounds of Formula (I) or a salt, isomer, prodrug, metabolite or polymorph thereof, which are CCR2 antagonists and are useful in preventing, treating or ameliorating CCR2 mediated inflammatory syndromes, disorders or diseases in a subject in need thereof.

  Formula (I)的替代二哌啶化合物或其盐、异构体、前药、代谢物或多型体，其为CCR2拮抗剂，可用于预防、治疗或改善需要的主体中的CCR2介导的炎症综合症、紊乱或疾病。